ONE-WAYDated event · through FY2025
Worldwide exclusive licensing-out of KRP-M223 to Novartis
An individual licensing-out theme involving a company-originated compound, KRP-M223, for which Novartis was granted exclusive worldwide rights to develop, manufacture, and commercialize the compound, and an upfront payment was received.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2025 →Last written FY2025
Directionhelps1 helps · 0 hurts · 0 flat